Royalty Pharma plc reported second quarter 2026 financial results and raised full-year guidance for Portfolio Receipts to $3,400 million–$3,500 million. Royalty Receipts grew 14% to $768 million, driven by Tremfya, Voranigo, Imdelltra, and Evrysdi, while total Portfolio Receipts increased 6% to $773 million. The company paid a quarterly dividend of $0.235 per share in the quarter and repurchased approximately 0.9 million shares for $45 million. Royalty Pharma acquired a royalty on AstraZeneca’s cliramitug for up to $425 million, bringing total Capital Deployment to over $1 billion in 2026. The company operates in the life sciences sector as a premier buyer of biopharmaceutical royalties and funder of innovation.